Results of a phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma

Investigational New Drugs

Volumn 27, Issue 5, 2009, Pages 476-481

  Garbo, Lawrence E ^a,b   Flynn, Patrick J ^a,c   MacRae, Margaret A ^a,d   Rauch, Mary A ^a   Wang, Yunfei ^a   Kolibaba, Kathryn S ^a,d  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b New York Oncology Hematology   (United States)

^c Minnesota Oncology and Hematology Professional Association   (United States)

^d Northwest Cancer Specialists   (United States)

Author keywords

Community based; Lymphoma; Multicenter; Phase II

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; GEMCITABINE; MITOXANTRONE; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; ASTHENIA; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; HYPOCALCEMIA; LEUKOPENIA; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70349320568     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9191-7     Document Type: Article

References (27)

1. NL Harris ES Jaffe J Diebold, et al. 2000 The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 Mod Pathol 13 2 193 207 10697278 10.1038/modpathol.3880035 1:STN:280:DC%2BD3c7mtVemsw%3D%3D (Pubitemid 30109108)
2. Jaffe E, Harris N, Stein H, Vardiman JW (eds) (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, France
3. F Bertoni E Zucca FE Cotter 2004 Molecular basis of mantle cell lymphoma Br J Haematol 124 2 130 140 14687022 10.1046/j.1365-2141.2003.04761.x 1:CAS:528:DC%2BD2cXhsVCktLw%3D (Pubitemid 38122184)
4. BT Hennessy EO Hanrahan PA Daly 2004 Non-Hodgkin lymphoma: an update Lancet Oncol 5 6 341 353 15172354 10.1016/S1470-2045(04)01490-1 (Pubitemid 38691037)
5. G Lenz M Dreyling E Hoster, et al. 2005 Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) J Clin Oncol 23 9 1984 1992 15668467 10.1200/JCO.2005.08.133 1:CAS:528:DC%2BD2MXjt1Cku7g%3D (Pubitemid 46211378)
6. National Comprehensive Cancer Network (NCCN) NCCN Clinical practice guidelines in oncology: Non-hodgkin's lymphoma, v.2.2008. http://www.nccn.org/ professionals/physician-gls/PDF/nhl.pdf
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Non-hodgkin's lymphoma, v.1.2005 (effective 6/21/05).
8. A Fossa A Santoro W Hiddemann L Truemper N Niederle S Buksmaui G Bonadonna S Seeber MR Nowrousian 1999 Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma J Clin Oncol 17 3786 3792 10577850 1:CAS:528:DC%2BD3cXhsVCitQ%3D%3D
9. A Santoro H Bredenfeld L Devizzi H Tesch V Bonfante S Viviani F Fiedler HS Parra C Benoehr M Pacini G Bonadonna V Diehl 2000 Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study J Clin Oncol 18 2615 2619 10893294 1:CAS:528:DC%2BD3cXltlKqt7k%3D (Pubitemid 30432529)
10. DG Savage SA Rule M Tighe TJ Garrett MW Oster RT Lee J Ruiz D Heitjan ML Keohan M Flamm SA Johnson 2000 Gemcitabine for relapsed or resistant lymphoma Ann Oncol 11 595 597 10907954 10.1023/A:1008307528519 1:STN:280: DC%2BD3M%2Fms1OgtA%3D%3D (Pubitemid 30431383)
11. C Dumontet F Morschhauser P Solal-Celigny, et al. 2001 Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma Br J Haematol 113 3 772 778 11380469 10.1046/j.1365-2141.2001.02795.x 1:CAS:528:DC%2BD3MXkvFehtrg%3D (Pubitemid 32524402)
12. D Maloney A Grillo-López C White, et al. 1997 IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90 2188 2195 9310469 1:CAS:528: DyaK2sXmtVOqsL0%3D (Pubitemid 27392702)
13. B Coiffier C Haioun N Ketterer, et al. 1998 Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 92 6 1927 1932 9731049 1:CAS:528:DyaK1cXmtVOhtbs%3D
14. JM Foran AZ Rohatiner D Cunningham, et al. 2000 European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol 18 2 317 324 10637245 1:CAS:528:DC%2BD3cXps1Oqsg%3D%3D
15. RA Gams S Bryan G Dukart, et al. 1985 Mitoxantrone in malignant lymphoma Invest New Drugs 3 2 219 222 4019123 10.1007/BF00174174 1:STN:280: DyaL2M3mtVGnug%3D%3D
16. R Fortstpointner M Dreyling R Repp, et al. 2004 The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 104 10 3064 3071 10.1182/blood-2004-04-1323 (Pubitemid 39517009)
17. C Wenger M Stern R Herrmann, et al. 2005 Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non-Hodgkin's lymphoma? Leuk Lymphoma 46 1 71 75 15621783 10.1080/10428190400007540 1:CAS:528:DC%2BD2cXhtFSntrzP
18. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D (Pubitemid 30099779)
19. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations JASA 53 457 481
20. C Traullé BB Coiffier 2005 Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma Future Oncol 1 3 297 306 16556002 10.1517/14796694.1.3.297
21. J Brody R Advani 2006 Treatment of mantle cell lymphoma: current approach and future directions Crit Rev Oncol Hematol 58 3 257 265 16751087 10.1016/j.critrevonc.2005.10.001 (Pubitemid 44425194)
22. H Schulz J Bohlius N Skoetz, et al. 2007 Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma Cochrane Database Syst Rev 4 CD003805 17943799
23. National Cancer Institute FDA Approval for Bortezomib. http://www.cancer.gov/cancertopics/druginfo/fda-bortezomib (accessed February 12, 2008)
24. A Goy A Younes P McLaughlin, et al. 2005 Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 23 4 667 675 15613697 10.1200/JCO.2005.03.108 1:CAS:528: DC%2BD2MXitVKisL0%3D (Pubitemid 46224166)
25. OA O'Connor J Wright C Moskowitz, et al. 2005 Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 23 4 676 684 15613699 10.1200/JCO.2005.02.050 (Pubitemid 46237441)
26. RC Kane R Dagher A Farrell, et al. 2007 Bortezomib for the treatment of mantle cell lymphoma Clin Cancer Res 13 18 Pt 1 5291 5294 17875757 10.1158/1078-0432.CCR-07-0871 1:CAS:528:DC%2BD2sXhtVCitL7F (Pubitemid 47510352)
27. P Barr R Fisher J Friedberg 2007 The role of bortezomib in the treatment of lymphomas Cancer Invest 25 8 766 775 18058474 10.1080/07357900701579570 1:CAS:528:DC%2BD2sXhtl2isrvK (Pubitemid 350223178)